Emerging treatment options for patients with recurrent advanced thymic epithelial tumors

References

• EngelsEAEpidemiology of thymoma and associated malignanciesJ Thorac Oncol2010510 Suppl 4S260S26520859116
   PubMed Web of Science ®Google Scholar
• StröbelPHohenbergerPMarxAThymoma and thymic carcinoma: molecular pathology and targeted therapyJ Thorac Oncol2010510 Suppl 4S286S29020859121
   PubMed Web of Science ®Google Scholar
• GirardNThymic tumors: relevant molecular data in the clinicJ Thorac Oncol2010510 Suppl 4S291S29520859122
   PubMed Web of Science ®Google Scholar
• GirardNShenRGuoTComprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomasClin Cancer Res200915226790679919861435
   PubMed Web of Science ®Google Scholar
• HeinoMPetersonPKudohJAutoimmune regulator is expressed in the cells regulating immune tolerance in thymus medullaBiochem Biophys Res Commun1999257382182510208866
   PubMed Web of Science ®Google Scholar
• MarxAHohenbergerPHoffmannHThe autoimmune regulator AIRE in thymoma biology: autoimmunity and beyondJ Thorac Oncol2010510 Suppl 4S266S27220859117
   PubMed Web of Science ®Google Scholar
• StröbelPMurumägiAKleinRDeficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)J Pathol2007211556357117334980
   PubMed Web of Science ®Google Scholar
• FornasieroADanieleOGhiottoCChemotherapy for invasive thymoma: a 13-year experienceCancer199168130332049749
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrKimKAisnerSCfor Eastern Cooperative Oncology Group; Southwest Oncology Group; Southeastern Cancer Study GroupCisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trialJ Clin Oncol1994126116411688201378
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrChenMKimKCisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trialJ Clin Oncol1997159309330999294472
   PubMed Web of Science ®Google Scholar
• LoehrerPJWangWAisnerSLong-term follow-up of patients with locally advanced or metastatic thymic malignancies: the Eastern Cooperative Oncology Group (ECOG) experiencePaper presented at: 40th American Society of Clinical Oncology Annual MeetingJune 5–8, 2004New Orleans, LA
   Google Scholar
• BonomiPDFinkelsteinDAisnerSEttingerDEST 2582 phase II trial of cisplatin in metastatic or recurrent thymomaAm J Clin Oncol19931643423458328413
   PubMed Web of Science ®Google Scholar
• UmemuraSSegawaYFujiwaraKA case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapyJpn J Clin Oncol200232726226512324577
   PubMed Web of Science ®Google Scholar
• FurugenMSekineITsutaKCombination chemotherapy with carboplatin and paclitaxel for advanced thymic cancerJpn J Clin Oncol20114181013101621742653
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrYiannoutsosCTDropchoSA phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinomaJ Clin Oncol20062418SAbstract 7079
   Google Scholar
• SchmittJLoehrerPJSrThe role of chemotherapy in advanced thymomaJ Thorac Oncol2010510 Suppl 4S357S36020859133
   PubMed Web of Science ®Google Scholar
• PalmieriGMerolaGFedericoPPreliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)Ann Oncol20102161168117219880439
   PubMed Web of Science ®Google Scholar
• IgawaSYanagisawaNMakitaSA case of recurrent invasive thymic cancer showing a stable disease to carboplatin plus paclitaxelGan To Kagaku Ryoho2010371121612163 Japanese21084818
   PubMedGoogle Scholar
• KoizumiTTakabayashiYYamagishiSChemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)Am J Clin Oncol200225326626812040285
   PubMed Web of Science ®Google Scholar
• KrenningEPKwekkeboomDJBakkerWHSomatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patientsEur J Nucl Med19932087167318404961
   PubMedGoogle Scholar
• FeroneDvan HagenPMvan KoetsveldPMIn vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cellsEndocrinology199914013733809886848
   PubMed Web of Science ®Google Scholar
• RinkeAMüllerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• LastoriaSVergaraEPalmieriGIn vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphyJ Nucl Med19983946346399544670
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrWangWJohnsonDHAisnerSCEttingerDSOctreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II TrialJ Clin Oncol200422229329914722038
   PubMed Web of Science ®Google Scholar
• BashaAMBonomiPDGlucocorticoid therapy for invasive thymoma progressing after chemotherapy: a review of 4 casesPaper presented at: 38th American Society of Clinical Oncology Annual MeetingMay 18–21, 2002Orlando, FL
   Google Scholar
• ZampaGTargeting the therapy: octreotide in thymoma relapseJ Clin Oncol20072518SAbstract 18199
   Google Scholar
• StröbelPHartmannMJakobAThymic carcinoma with over-expression of mutated KIT and the response to imatinibN Engl J Med2004350252625262615201427
   PubMed Web of Science ®Google Scholar
• NakagawaKMatsunoYKunitohHMaeshimaAAsamuraHTsuchiyaRImmunohistochemical KIT (CD117) expression in thymic epithelial tumorsChest2005128114014416002927
   PubMed Web of Science ®Google Scholar
• AllanderSVNupponenNNRingnérMGastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profileCancer Res200161248624862811751374
   PubMed Web of Science ®Google Scholar
• GiacconeGRajanARuijterRSmitEvan GroeningenCHogendoornPCImatinib mesylate in patients with WHO B3 thymomas and thymic carcinomasJ Thorac Oncol20094101270127320197733
   PubMed Web of Science ®Google Scholar
• SalterJTLewisDYiannoutsosCTLoehrerPJRisleyLChioreanEGImatinib for the treatment of thymic carcinomaJ Clin Oncol200826SAbstract 8116
   Web of Science ®Google Scholar
• PalmieriGMarinoMBuonerbaCImatinib mesylate in thymic epithelial malignanciesCancer Chemother Pharmacol201269230931521710245
   PubMed Web of Science ®Google Scholar
• TsuchidaMUmezuHHashimotoTAbsence of gene mutations in KIT-positive thymic epithelial tumorsLung Cancer200862332132518486988
   PubMed Web of Science ®Google Scholar
• YohKNishiwakiYIshiiGMutational status of EGFR and KIT in thymoma and thymic carcinomaLung Cancer200862331632018448188
   PubMed Web of Science ®Google Scholar
• SchirosiLNanniniNNicoliDActivating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitorsAnn Oncol Epub February 21, 2012
   Web of Science ®Google Scholar
• BisagniGRossiGCavazzaASartoriGGardiniGBoniCLong lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinomaJ Thorac Oncol20094677377519461405
   PubMed Web of Science ®Google Scholar
• DişelUOztuzcuSBeşenAAPromising efficacy of sorafenib in a relapsed thymic carcinoma with c-KIT exon 11 deletion mutationLung Cancer201171110911220970876
   PubMed Web of Science ®Google Scholar
• LiXFChenQHuangWXYeYBResponse to sorafenib in cisplatin-resistant thymic carcinoma: a case reportMed Oncol200926215716018846437
   PubMed Web of Science ®Google Scholar
• StröbelPBargouRWolffASunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experienceBr J Cancer2010103219620020571495
   PubMed Web of Science ®Google Scholar
• FiedlerWGiacconeGLaschPPhase I trial of SU14813 in patients with advanced solid malignanciesAnn Oncol201122119520120605934
   PubMed Web of Science ®Google Scholar
• AisnerSCDahlbergSHameedMREpidermal growth factor receptor, c-KIT, and HER2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group studyJ Thorac Oncol20105688589220421818
   PubMed Web of Science ®Google Scholar
• FarinaGGarassinoMCGambacortaMLa VerdeNGherardiGScanniAResponse of thymoma to cetuximabLancet Oncol20078544945017466903
   PubMed Web of Science ®Google Scholar
• PalmieriGMarinoMSalvatoreMCetuximab is an active treatment of metastatic and chemorefractory thymomaFront Biosci20071275776117127335
   PubMed Web of Science ®Google Scholar
• PalmieriGMontellaLMerolaGClinical outcome of patients with thymic epithelial tumorsJ Clin Oncol20072518SAbstract 14148
   Google Scholar
• ChristodoulouCMurraySDahabrehJResponse of malignant thymoma to erlotinibAnn Oncol20081971361136218534960
   PubMed Web of Science ®Google Scholar
• KurupABurnsMDropchoSPaoWLoehrerPJPhase II study of gefitinib treatment in advanced thymic malignanciesJ Clin Oncol20052316SAbstract 7068
   Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• BedanoPMPerkinsSBurnsMA phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinomaJ Clin Oncol200826SAbstract 19087
   Web of Science ®Google Scholar
• MeisterMSchirmacherPDienemannHMutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomasCancer Lett2007248218619116919868
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLA phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumorsClin Cancer Res200814380481018245542
   PubMed Web of Science ®Google Scholar
• MarksPARichonVMRifkindRAHistone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cellsJ Natl Cancer Inst200092151210121610922406
   PubMed Web of Science ®Google Scholar
• GiacconeGRajanABermanAPhase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsJ Clin Oncol201129152052205921502553
   PubMed Web of Science ®Google Scholar
• ThomasARajanAKhozinSA phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignanciesPaper presented at: 48th American Society of Clinical Oncology Annual MeetingJune 1–5, 2012Chicago, IL
   Google Scholar
• ZucaliPAPetriniILorenziEInsulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomasCancer2010116204686469520597130
   PubMed Web of Science ®Google Scholar
• HaluskaPShawHMBatzelGNPhase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsClin Cancer Res200713195834584017908976
   PubMed Web of Science ®Google Scholar
• RajanARielyGJCarterCAPhase II study of cixutumumab (IMC-A12) in thymic malignanciesPaper presented at: 48th American Society of Clinical Oncology Annual MeetingJune 1–5, 2012Chicago, IL
   Google Scholar
• KimDJYangWIKimSHParkIKChungKYExpression of neurotrophin receptors in surgically resected thymic epithelial tumorsEur J Cardiothorac Surg200528461161616125946
   PubMed Web of Science ®Google Scholar
• RajanABermanAKellyRJPhase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC)J Clin Oncol201028SAbstract e17525
   Web of Science ®Google Scholar
• WheelerDLIidaMDunnEFThe role of Src in solid tumorsOncologist200914766767819581523
   PubMed Web of Science ®Google Scholar
• WakeleeHAGubensMABurnsMA phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignanciesPaper presented at: Chicago Multidisciplinary Symposium in Thoracic OncologyDecember 9–11, 2010Chicago, IL
   Google Scholar